Maypro to distribute NZMP’s HN001 & HN019 Probiotics in N. America

The agreement will also cover new strains in development, according to a release.

BifidoB HN019 and LactoB HN001 have been available in North America, but the agreement with Maypro allows for greater distribution and additional customer support, a spokesperson told us. The strains are supported by data from over 60 combined clinical trials supporting a range of consumer benefits, including digestive health, immunity, skin health, women's health and post-natal depression.

Clinical trials have shown a range of consumer benefits, including digestive health, immunity, skin health, women's health and post-natal depression.

"This agreement with Maypro is important to brands already using probiotic ingredients as well brands looking to develop new products with health claims in mood, stress, anxiety, skin health, digestive health and immunity,"​ said Chris Ireland, senior manager business development, NZMP. "This agreement will allow us to both extend our sales force and harness Maypro's valuable supplement customer network."​

Demand for probiotics is increasing across North Americas, with data from FMCG Gurus’ Q4 2020 Probiotic Survey reporting that the proportion of North American consumers who stated they purchased probiotic products in the past twelve months increased from 45% to 61% from 2018 to 2020.

NZMP's probiotics strains have comprehensive certifications, including vegan, vegetarian, non-dairy, organic, halal, kosher and non-GMO project verified and have proven strong stability in a variety of traditional supplement applications such as capsules and sachets, yogurts, ice creams, chocolate and coatings and high-pressure processed juices.